P3 Health Partners Inc. — Form 10-Q
Filed August 10, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 72/100
What the filing says
On April 27, 2026, P3 Health Group LLC executed a Second Amended and Restated LLC Agreement effective that date. Concurrent debt exchange converted approximately $252.48M in outstanding promissory notes (principal, accrued interest, back-end fees) into Series A (13.5%), Series B (17.5%), and Series C (19.5%) Cumulative Preferred Stock. Separately, P3 Health Partners Inc. sold Series D Preferred Stock (19.5%) via Securities Purchase Agreement on same date. The LLC now holds 650,000 Series A, 555,000 Series B, 2,335,000 Series C, and 1,100,000 Series D Preferred Units corresponding to the Corporation's Preferred Stock holdings.
Why this rating
Large debt-to-equity conversion (~$252M) restructures capital stack materially. Relative to $39.1M market cap, event is ~6.4x company size—material refinancing. Neutral impact: conversion is typical refinancing, not transformational gain/loss, and no business operational change disclosed.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.